Lyne Villeneuve, M.Sc

Research professional and clinical studies coordinator
Bachelor in microbiology, Master degree in pharmacy
Joined in : 2001

Nickname : Lynus
Likes : troubleshooting everyone in the lab
Dislikes : disorder in the cell culture stuff


List of publications


Audet-Delage Y, Grégoire J, Caron P, Turcotte V, Plante M, Ayotte P, Simonyan D, Villeneuve L, Guillemette C. Estradiol metabolites as biomarkers of endometrial cancer prognosis after surgery. J Steroid Biochem Mol Biol. 2017 Oct 29. [Epub ahead of print] PubMed PMID: 29092787.

Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D’Andrea M, Villeneuve L, Toffoli G, Guillemette C. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Front Pharmacol. 2017 Oct 10;8:712. eCollection 2017. PubMed PMID: 29066969.

Rouleau M, Tourancheau A, Girard-Bock C, Villeneuve L, Vaucher J, Duperré AM, Audet-Delage Y, Gilbert I, Popa I, Droit A, Guillemette C. Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing. Cell Rep. 2016 Sep 27;17(1):114-24. PubMed PMID: 27681425.

Girard-Bock C, Benoit-Biancamano MO, Villeneuve L, Desjardins S, Guillemette C. A Rare UGT2B7 Variant Creates a Novel N-Glycosylation Site at Codon 121 with Impaired Enzyme Activity. Drug Metab Dispos. 2016 Dec;44(12):1867-1871. Epub 2016 Sep 9. PubMed PMID: 27612916.

Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, Guillemette C. Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. Pharmacogenomics J. 2017 Apr 25. [Epub ahead of print] PubMed PMID: 28440341.

Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.  ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015 Dec;25(12):573-83. PubMed PMID: 26352872.

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. Eur Urol. 2016 Apr;69(4):601-9. Epub 2015 Jul 26. PubMed PMID: 26215610.

Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C. Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Drug Metab Dispos. 2015 Sep;43(9):1331-5. Epub 2015 Jun 15. PubMed PMID: 26076694.

Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A, Guillemette C. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA
sequencing. Pharmacogenomics J. 2016 Feb;16(1):60-70. Epub 2015 Apr 14. PubMed PMID: 25869014.

Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette C. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. Pharmacogenomics J. 2015 Dec;15(6):513-20. Epub 2015 Mar 17. PubMed PMID: 25778466.

Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015 Apr;43(4):611-9. Epub 2015 Feb 3. PubMed PMID: 25650382.

Rouleau M, Roberge J, Falardeau SA, Villeneuve L, Guillemette C., The Relative Protein Abundance of UGT1A Alternative Splice Variants as a Key Determinant of Glucuronidation Activity In Vitro. Drug Metab Dispos. 2013 Apr;41(4):694-7. Epub 2013 Jan 29.

Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, Guillemette C. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9. Epub 2010 Dec 8.

Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab. 2010 Jun;95(6):2689-98. Epub 2010 Apr 6.

McGrath M, Lepine J, Lee IM, Villeneuve L, Buring J, Guillemette C, De Vivo I. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genomics. 2009 Mar;19(3):239-43.

Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C. Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.

Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, Guillemette C. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res. 2008 Sep 26;644(1-2):56-63. doi: 10.1016/j.mrfmmm.2008.07.002. Epub 2008 Jul 16.

Betônico GN, Abbud-Filho M, Goloni-Bertollo EM, Alvarenga MP, Guillemette C, Villeneuve L, Benoit-Biancamano MO, Pavarino-Bertelli EC. Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side
effects in kidney transplant patients. Transplant Proc. 2008 Apr;40(3):708-10.

Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006 Jul;34(7):1220-8. Epub 2006 Apr 4.

Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res. 2006 Mar 15;12(6):1850-8.

Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology. 2005 Aug;42(2):448-57.

Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez FJ, Staels B. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol. 2005
Jan;67(1):241-9. Epub 2004 Oct 6.

Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004 Aug;14(8):501-15.

Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003 Oct;307(1):117-28. Epub 2003 Aug 27.

Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J
Biol Chem. 2003 Apr 18;278(16):13975-83. Epub 2003 Feb 11.